study to evaluate different extended release (ER)-formulations and multiple ascending dosing of AZD3241

Study identifier:D0490C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Extended Release Tablets of AZD3241 after Administration of Multiple Ascending Doses in Healthy Male and Female Volunteers including food effect

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD3241, Placebo Tablet

Sex

All

Actual Enrollment

Study type

Interventional

Age

30 Years - 65 Years

Date

Study Start Date: 01 Jun 2009

Primary Completion Date: 01 Mar 2010

Study Completion Date: 01 Mar 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Apr 2010 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Uppsala, Sweden

Arms	Assigned Interventions
Experimental: AZD3241 AZD3241 Tablets	Drug: AZD3241 Oral Tablet, Repeated Administration
Experimental: Placebo Placebo Tablets	Drug: Placebo Tablet Oral Tablet. Repeated Administration

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

Charlotta Naeslund

+46 18 431 1336

charlotta.naeslund@quintiles.com

Investigators

Principal Investigator

Rolf Karlsten

Medical Science Director AstraZeneca R&D Södertälje.